Last reviewed · How we verify
Mesotherapy
Mesotherapy is a Biologic drug developed by Hadassah Medical Organization. It is currently in Phase 1 development. Also known as: Vaxigrip Trivalent Influenza vaccine , diluted 1:10..
Mesotherapy involves intradermal or subcutaneous injections of various substances, including pharmaceutical preparations, enzymes, hormones, plant extracts, vitamins, and hyaluronic acid. The clinical efficacy of mesotherapy has not been proven, and it is considered an alternative medicine with poor scientific backing.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Mesotherapy |
|---|---|
| Also known as | Vaxigrip Trivalent Influenza vaccine , diluted 1:10. |
| Sponsor | Hadassah Medical Organization |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparison of Mesotherapy Treatment Doses in Patients With Chronic Non-Specific Neck Pain (NA)
- Comparison of the Efficacy of Mesotherapy and Extracorporeal Shock Wave Therapy in Patients With Lateral Epicondylitis (NA)
- Can Blood Biomarkers of Inflammation and BDNF be Used to Assess the Effectiveness of Collagen Mesotherapy in Chronic CMPS?
- Regenerative Treatment of Female Genital Atrophy (PHASE1, PHASE2)
- Comparison of Effectiveness of Tranexamic Acid Mesotherapy Versus Glutathione Mesotherapy in Post Burn Facial Hyperpigmentation (PHASE2)
- Evaluation of Exosomes Injection in Treatment of Male Androgenetic Alopecia: Clinical and Immunohistochemical Study (PHASE1, PHASE2)
- Mesotherapy Treatment of Irritable Bowel Syndrome (PHASE2)
- Comparison of the Efficacy of Dextrose Prolotherapy and Mesotherapy in Lateral Epicondylitis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mesotherapy CI brief — competitive landscape report
- Mesotherapy updates RSS · CI watch RSS
- Hadassah Medical Organization portfolio CI
Frequently asked questions about Mesotherapy
What is Mesotherapy?
Who makes Mesotherapy?
Is Mesotherapy also known as anything else?
What development phase is Mesotherapy in?
Related
- Manufacturer: Hadassah Medical Organization — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Vaxigrip Trivalent Influenza vaccine , diluted 1:10.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing